FKONCO

Fresenius Kabi Oncology Limited has informed the Exchange that Dr. Patricia Grigoleit , Non-Executive Director of the Company, has resigned from the directorship of the Company with effect from December 11, 2013.

Fresenius Kabi Oncology Limited has informed the Exchange that Mr. Rajiv Lochan Jain has been appointed as an Additional Director of the Company w.e.f. October 03, 2013 under "Independent Category" via Board of Directors Resolution passed by circulation on October 07, 2013.

Fresenius Kabi Oncology Limited has informed the Exchange that "Mr. Thomas Georg Mechtersheimer, Non Executive Director of the Company, has sent his resignation from the directorship of the Company with effect from August 31, 2013".

Fresenius Kabi Oncology Limited has informed the Exchange that Mr. Rajiv Lochan Jain has been appointed as an Additional Director of the Company w.e.f. August 06, 2013 under "Independent Category".

Fresenius Kabi Oncology Limited has submitted to the Exchange a copy of an abstract of the terms and condition regarding re-appointment of Mr. Peter F. Nilsson as the Managing Director & CEO of the Company for a further period of two year i.e. from October 20, 2013 to October 19, 2015.

Fresenius Kabi Oncology Limited has informed the Exchange that Mr. Nitin Potdar, Independent Director, has resigned from the directorship of the Company with immediate effect.

Fresenius Kabi Oncology Limited has informed the Exchange that the Board of Directors of the Company at their meeting held on February 13, 2013 the Board interalia, approved/took note of the following: (1) Appointment of Dr. Patricia Grigoleit as an Additional Director of the Company w.e.f. February 13, 2013; (2) Appointment of Dr. Satish B. Kulkarni as an Alternate Director in place of Mr. Thomas George Mechtersheimer. This appointment was effective for the Board Meeting dated February 13, 2013 and Dr. Kulkarni resigned from the Alternate Directorship at the conclusion of the meeting.

Fresenius Kabi Oncology Limited has informed the Exchange that the Board of Directors of the Company has taken on record the resignation of Dr. Anand C. Burman as the Non-Executive Director of the Company w.e.f. February 02, 2012.

Fresenius Kabi Oncology Limited has informed the Exchange vide its letter dated January 20, 2010 that : In the recently concluded meeting of the Board of Directors of the Company, the following matters have been considered and approved / noted : 1) Mr. Mats Christer Henriksson has been appointed as the Director w.e.f. January 20, 2010, in order to fill up the casual vacancy necessitated due to resignation of Mr. John Robert Ducker from the Board of Directors of the Company; 2) The Board also took note about the execution of a long term lease agreement for shifting of Corporate Office and R & D

Fresenius Kabi Oncology Limited has informed the Exchange that "Mr. John Robert Ducker, Director of the Company, has resigned from the Directorship of the Company w.e.f. January 13, 2010".

Dabur Pharma Limited has informed the Exchange that the Company has appointed new CFO Mr. Peter Neilsson, w.e.f. November 01, 2008 in place of Mr. Shailendra Tandon, who has relinquished his office from the same date. Further, the company has informed the Exchange that the e-mail of Investor Grievance has changed as follows: avaneesh.singh@daburpharma.com.

Dabur Pharma Limited has informed the Exchange that: "Mr. Ajay Kumar Vij has resigned from the Board as Director of the Company w.e.f. the close of business hours on Friday, 8th August 2008. Further to inform that Mr. Ajay Kumar Vij will continue as Chief Executive Officer of the Company".

Dabur Pharma Limited has informed the Exchange that Mr. C K Birla has, vide letter dated August 29, 2007, submitted his resignation from the Board as an Independent Director w.e.f. August 29, 2007.

Dabur Pharma Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on July 26, 2007 has inter alia, taken the following decisions: (1) Dr Anand C Burman has stepped down from the Non-Executive Chairmanship and has been appointed as Managing Director of the Company. (2) Mr. Mohit Burman has been appointed as Additional Director and Non-Executive Chairman of the Company. (3) Approved appointment of Mr. Nikhil Kulshreshtha, Company Secretary and Head - Legal as its new Compliance Officer.

Dabur Pharma Limited has informed the Exchange that: "Mr. Nikhil Kulshreshtha has been appointed as "Company Secretary and Head-Legal" of Dabur Pharma Limited w.e.f July 21, 2007".

Dabur Pharma Limited has informed the Exchange that Mr. Shailendra Tandon has joined the Company as Chief Financial Officer w.e.f. June 26, 2007. Mr. Shailendra Tandon will sign all the documents, papers & filing etc. as per stock Exchange requirements till Company Secretary/Compliance officer is appointed.

Dabur Pharma Limited has informed the Exchange that: "Mr. Gauri Shankar Mishra has resigned as Company Secretary of the Company w.e.f. 19th June, 2007. The Company is in the process of appointing a new Company Secretary in his place".

Dabur Pharma Limited has informed the Exchange that "Mr. Vardhan Dharkar has resigned as Chief Financial Officer of the Company w.e.f. 1st June, 2007 and accordingly also relinquished his position as the Compliance Officer, effective the above said date. The Company is in the process of appointing a new Compliance Officer in his place".

Dabur Pharma Limited has informed the Exchange that: "Mr. G S Mishra has been appointed as a Company Secretary of Dabur Pharma Limited".

Dabur Pharma Limited has informed the Exchange that Mr. V. V. Dharkar has joined the Company as Chief Financial Officer w.e.f December 01, 2006. He will sign all the documents, papers & filling etc, as per Stock Exchange requirements till Company Secretary / Compliance Officer is appointed.

Dabur Pharma Limited has informed the Exchange that the Compliance Officer of the Company Mr. Pankaj Kapdeo, Company Secretary has resigned from the Company w.e.f. July 19,2006 and the Company is in the process of appointing another Compliance Officer/Company Secretary.

Dabur Pharma Limited has informed the Exchange that Dr. P.S.Srinivasan, Whole time Director of the Company, has resigned form the Board of Directors effective April 18, 2005.